While pembrolizumab, nivolumab, and dostarlimab were thoroughly examined in the context of CRC treatment, there are other PD-1/PD-L1 pathway targeting antibodies, such as AMP-224, atezolizumab, avelumab, camrelizumab, durvalumab, envafolimab, sintilimab, spartalizumab, tislelizumab, and toripalimab, at various stages of development. This evidence concerns the gene PDCD1 and colorectal carcinoma.